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Abstract Ceramide-1-phosphate (Cer-1-P) is emerging as a
novel bioactive sphingolipid. It is formed by phosphorylation
of ceramide catalyzed by ceramide kinase, and has been impli-
cated in di¡erent cellular processes. Cer-1-P is mitogenic for
¢broblasts, blocks apoptosis in macrophages, controls phagocy-
tosis in neutrophils, and mediates in£ammatory responses. Only
recently have we started to uncover the signaling pathways that
are a¡ected by Cer-1-P. Recent work has demonstrated that
cytosolic phospholipase A2 and acid sphingomyelinase are direct
intracellular targets of Cer-1-P, and that it may also induce
phosphorylation of extracellular signal-regulated kinase-2 and
calcium mobilization. These actions of Cer-1-P seem to be
cell type-speci¢c.
* 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The discovery by Hannun and co-workers [1] of the inhibi-
tion of protein kinase C (PKC) by sphingosine in 1986
marked the beginning of a new era in research of lipid signal
transduction. In 1987, Kolesnick [2] demonstrated the stimu-
lation of an acid, but not neutral, sphingomyelinase (SMase)
activity by exogenous addition of 1,2-dioctanoylglycerol (a
permeable analog of diacylglycerol) to GH3 pituitary cells.
This action caused sphingomyelin (SM) hydrolysis and a con-
comitant increase in ceramide levels that were independent of
PKC. It was suggested that sphingolipid-derived metabolites
might function as second messengers. This hypothesis was
con¢rmed independently by Hannun’s and Kolesnick’s groups
with the elucidation of the SM pathway and the physiologic
functions of ceramide [3^8]. It is now well established that
ceramides regulate a variety of physiological or pathophysio-
logical functions including cell proliferation, di¡erentiation,
apoptosis, and in£ammation [3^10]. To achieve this, ceram-
ides modulate diverse signal transduction pathways by acti-
vating or inhibiting key regulatory enzymes including speci¢c
serine/threonine kinases [8,11], protein phosphatases [12],
PKCj [13], stress-activated protein kinases also known as
Jun nuclear kinases [14,15], mitogen-activated protein kinases
(MAPKs) [16,17], phospholipase A2 (PLA2) [18], protein ki-
nase B [19,20], and phospholipase D (PLD) [21,22] (Fig. 1).
Ceramide formation serves di¡erent functions at distinct lo-
cations in the cell, and probably the topology of ceramide
generation may be a crucial determinant of its impact on
cell physiology. However, it is unclear how cells separate sig-
naling pools from metabolic pools. Also, enzymes of ceramide
metabolism show distinct subcellular localization and topolo-
gy (reviewed by Hannun and Obeid [23]). For instance, the
plasma membrane of cells contains caveola-associated neutral
SMase and a fraction of acid SMase, and the ceramides that
are generated by these enzymes may have di¡erent functions.
For details on SMase activities, enzymology, and compart-
mentalization, see [24^26]. Ceramide generation at the plasma
membrane exerts distinct and speci¢c functions including in-
hibition of PKC translocation or aggregation of the Fas re-
ceptor, but not other e¡ects mediated by endogenous ceram-
ides such as apoptosis or cell cycle arrest [23]. Lysosomal acid
SMase-derived ceramides may activate cathepsin D, and the
ceramides that are generated in the endoplasmic reticulum,
which is the primary site of de novo synthesis of ceramide,
have been implicated in mediating apoptosis. The nucleus and
mitochondria have also been implicated as sites of ceramide
generation, with possible roles in apoptosis [23]. In addition,
little is known concerning SM synthase, the enzyme respon-
sible for transferring phosphocholine from phosphatidylcho-
line to ceramide generating diacylglycerol and SM in cells.
This enzyme activity has been implicated in cell regulation
and transformation through its ability to modulate the levels
of ceramide and diacylglycerol, and it may account, at least in
part, for some of the e¡ects previously attributed to phospha-
tidylcholine-speci¢c phospholipase C [27]. Because natural
ceramides are not permeant to cell membranes, many of the
studies to determine the role of ceramides in signal transduc-
tion are carried out using short-chain cell-permeable analogs,
or by exogenous addition of bacterial SMase to cells main-
tained in culture. However, Ji et al. [28] developed a solvent
mixture consisting of ethanol/dodecane (98:2, v/v) that al-
lowed dispersion of natural long-chain ceramide in aqueous
solutions, and facilitated its uptake by cells. Using this solvent
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mixture, exogenous ceramide could mimic many of the e¡ects
of ceramide-producing agonists such as tumor necrosis factor-
K [28]. In addition, ceramide is the precursor of other bioac-
tive sphingolipids that can also regulate cellular functions.
Stimulation of ceramidases generates sphingosine (Fig. 2),
which can control the activity of key enzymes involved in
the regulation of metabolic or cell signaling pathways (i.e.
inhibition of the Mg2þ-dependent form of phosphatidate
(PA) phosphohydrolase [29,30], inhibition of PKC [1], activa-
tion of PLD [31], and stimulation of diacylglycerol kinase
[32,33]). Many of the e¡ects of sphingosine are known to be
mediated through its conversion to sphingosine-1-phosphate
(Sph-1-P) [34]. However, this may not always be the case
since, for instance in rat ¢broblasts, Sph-1-P stimulates PLD
rapidly and potently, whereas sphingosine is a slow and weak
activator of this enzyme activity [22]. Sph-1-P was ¢rst de-
scribed as a mitogen for cultured ¢broblasts [35] and subse-
quently has been implicated in the regulation of other cellular
processes including cell di¡erentiation, migration, angiogene-
sis and cell survival [36^39]. More recently, our group has
demonstrated that Sph-1-P stimulates cortisol secretion in
cells of the zona fasciculata of bovine adrenal glands, thereby
implicating Sph-1-P in the regulation of steroidogenesis [40].
The observation that Sph-1-P binds to speci¢c cell surface G
protein-coupled receptors, together with the discovery that it
can be generated intracellularly by the action of growth fac-
tors, such as platelet-derived growth factor, points out that
Sph-1-P can function as both ¢rst and second messenger [38].
These actions of Sph-1-P may di¡erentially a¡ect speci¢c in-
tracellular targets or signaling pathways. In this connection, it
has been recently demonstrated that only intracellularly gen-
erated Sph-1-P plays a role in the regulation of GTP cyclo-
hydrolase, thereby leading to tetrahydrobiopterin biosynthesis
and subsequent stimulation of inducible nitric oxide synthase
[41] (Fig. 1).
Another important metabolite that can be generated from
ceramide is ceramide-1-phosphate (Cer-1-P), which is formed
by the action of ceramide kinase (Fig. 2). There is increasing
evidence suggesting that Cer-1-P is implicated in the regula-
tion of vital cellular processes, such as cell proliferation
[42,43], apoptosis [44], phagocytosis [45], and in£ammation
[46,47]. The purpose of this article is to review the role of
Cer-1-P as a new bioactive lipid capable of regulating cell
activation, and to emphasize the consequences of modifying
Cer-1-P levels in cells.
2. Occurrence of Cer-1-P in mammalian cells
Ceramide kinase was ¢rst identi¢ed in brain synaptic
vesicles by Bajjalieh and co-workers [48], and subsequently
found in human leukemia (HL-60) cells by Kolesnick and
Hemer [11]. Cer-1-P was then found by Dressler and Koles-
nick also in HL-60 cells [49]. The latter authors suggested the
possibility that a pathway from SM to Cer-1-P via phosphor-
ylation of ceramide by ceramide kinase existed in cells. More
recently, Hinkovska-Galcheva et al. [45] observed that endog-
enous Cer-1-P can be generated during the phagocytosis of
antibody-coated erythrocytes in human neutrophils that were
primed with formylmethionylleucylphenylalanine. Also, Rile
et al. [50] reported that Cer-1-P can be formed in neutrophils
Fig. 1. Some downstream targets of ceramide, sphingosine and sphingosine-1-phosphate. (1) Ceramidase; (2) ceramide synthase; (3) sphingosine
kinase; (4) sphingosine-1-phosphate phosphatase. Abbreviations: AC, adenylyl cyclase; BH4, tetrahydrobiopterin; CAPP1, ceramide-activated
protein phosphatase 1; CAPP2A, ceramide-activated protein phosphatase 2A; ERK, extracellular signal-regulated kinases; GTPCH, GTP cy-
clohydrolase; KSR, kinase suppressor of Ras; iNOS, inducible nitric oxide synthase; PAP, phosphatidate phosphohydrolase; LPPs, lipid phos-
phate phosphatases; Rb, retinoblastoma protein; PI3-K, phosphatidylinositol 3-kinase; PKC, protein kinase C; PLD, phospholipase D; SAPK/
JNK, stress-activated protein kinase/Jun N-terminal kinase.
Fig. 2. Generation of bioactive sphingolipids in mammalian cells.
Ceramide is produced by the action of SMase on SM. Ceramide
can then be converted to ceramide-1-phosphate by ceramide kinase.
The reverse reaction is catalyzed by ceramide-1-phosphate phospha-
tase. Alternatively, ceramide can be acted upon by ceramidases to
form sphingosine, which can, in turn, be phosphorylated to sphingo-
sine-1-phosphate. The reverse reaction is catalyzed by sphingosine-1-
phosphate phosphatase. SMase D would generate ceramide-1-phos-
phate directly from SM, but this activity has not been found in
mammalian cells. Likewise, interconversion of ceramide-1-phosphate
and sphingosine-1-phosphate does not seem to occur in mammals.
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upon addition of exogenous cell-permeable [3H]N-hexanoyl-
sphingosine (C6-ceramide) to the cells, and Riboni and co-
workers [51] have demonstrated that Cer-1-P can be generated
from both SM-derived ceramide and the recycling of sphingo-
sine produced by ganglioside catabolism, in cerebellar granule
cells. Cer-1-P can also be generated by the action of interleu-
kin 1-L on A549 lung carcinoma (epithelial-derived) cells [46].
More recently, we found that Cer-1-P is present in normal
bone marrow-derived macrophages isolated from healthy
mice, and that Cer-1-P plays a critical role in cell survival [44].
3. Biological functions of Cer-1-P
Although the existence of Cer-1-P in mammalian cells has
been known for some time, no biologic activity had been
assigned to this bioactive lipid until we demonstrated that it
stimulates DNA synthesis and promotes cell division in rat
¢broblasts [42] (Fig. 3). The latter studies were performed
using synthetic short-chain Cer-1-Ps (C2-Cer-1-P and C8-
Cer-1-P) and therefore, these e¡ects were regarded as phar-
macological in nature. Progress in understanding the func-
tions of Cer-1-P has been slow probably because the enzymes
that regulate its metabolism have not been de¢nitively identi-
¢ed or cloned. Cer-1-P can be considered a sphingoid analog
of PA or lyso-PA, two well-known mitogenic agents for ¢bro-
blasts [21,52,53]. Of interest, Cer-1-P was more potent than
PA or lyso-PA at stimulating DNA synthesis and cell division.
In particular, maximal incorporation of thymidine into DNA
occurred at concentrations of short-chain Cer-1-Ps that were
5^10-fold lower than those of PA and lyso-PA. In those stud-
ies, the phospholipids were presented sonicated in water to
cells in culture [21,42]. However, exogenous natural (long-
chain) Cer-1-P, which was obtained from bovine brain and
contained predominantly stearic and nervonic acids, was not
e¡ective at stimulating DNA synthesis unless it was dispersed
in a solvent mixture of methanol/dodecane (49:1, v/v) [43].
Like short-chain Cer-1-Ps, natural (long-chain) Cer-1-P stimu-
lated DNA synthesis potently. This action was accompanied
by an increase in the levels of proliferating cell nuclear antigen
[43], a cell cycle regulator that is present at sites of ongoing
DNA synthesis [54]. Another important observation was that
Cer-1-P is implicated in phagocytosis. Priming of human neu-
trophils with formylmethionylleucylphenylalanine followed by
addition of IgG-opsonized erythrocytes produced rapid for-
mation of intracellular Cer-1-P, which was associated with
phagolysosome formation [45]. To date, little is known about
the metabolic pathways that are regulated by Cer-1-P, but
unlike other related mitogenic phospholipids, including Sph-
1-P, lyso-PA or PA, Cer-1-P does not a¡ect PLD, MAPK
(extracellular signal-regulated kinase (ERK)-1/2), adenylyl cy-
clase, Ca2þ mobilization, or the expression of the early genes
c-fos or c-myc in rat or mouse ¢broblasts [42,43]. However,
induction of ERK-2 phosphorylation, but not ERK-1, by
Cer-1-P has been shown in osteoblastic cells [55], and C2-
Cer-1-P-induced Ca2þ mobilization has been shown to occur
in calf pulmonary artery endothelial cells [56] and thyroid
FRTL-5 [57]. Nonetheless, Cer-1-Ps did not induce Ca2þ mo-
bilization in ¢broblasts [42,43], neutrophils [50], or A549 cells
[47], and C8-Cer-1-P only had a marginal e¡ect on Ca2þ mo-
bilization in FRTL-5 cells [57]. Therefore, this e¡ect of Cer-1-
P remains controversial. From the above results it can be
concluded that the e¡ects of Cer-1-P are cell type-speci¢c.
It was previously reported that C8-Cer-1-P caused modest
increases in the size of cultured chick otic vesicle explants, and
that it decreased cell death in serum-starved cultured explants
[58]. More recently, our lab has shown that Cer-1-P blocks
cell death in bone marrow-derived macrophages incubated in
the absence of macrophage-colony stimulating factor [44], a
condition known to induce apoptosis in these cells [59,60].
Cer-1-P blocked both DNA fragmentation and the stimula-
tion of the caspase-9/caspase-3 pathway, thereby suggesting
that the prosurvival e¡ect of Cer-1-P was due to inhibition
of apoptosis [44]. Apoptotic macrophages showed high levels
of ceramides and enhanced acid SMase activity compared to
healthy cells [39,60]. A key observation was that Cer-1-P com-
pletely blocked acid SMase activity in intact macrophages
[44], thereby preventing the accumulation of ceramides and
promoting cell survival (Fig. 3). Acid SMase was also inhib-
ited by Sph-1-P in intact macrophages [39]. However, unlike
Sph-1-P, the inhibitory e¡ect of Cer-1-P involved direct phys-
ical interaction with the enzyme, as Cer-1-P also inhibited acid
SMase in cell homogenates [44]. This observation supports the
hypothesis that the actions of Cer-1-P on intact cells are not
mediated through receptor interaction. Also, apoptosis was
associated with a substantial decrease in intracellular Cer-1-
P, which can account, at least in part, for the activation of
acid SMase [44]. This may be relevant, because Cer-1-P could
be a physiological inhibitor of acid SMase, necessary for keep-
ing its activity low under normal conditions.
Two recent reports by Pettus and co-workers showed that
ceramide kinase mediates cytokine- and Ca2þ ionophore-in-
duced arachidonic acid release and prostanoid synthesis, and
that Cer-1-P is a direct activator of cytosolic phospholipase
A2 in A549 lung carcinoma cells [46,47], a cell line lacking
lipoxygenases and cytochrome P450. Speci¢cally, incubation
of these cells with interleukin-1L and the Ca2þ ionophore
A23187 induced an increase in Cer-1-P levels that coincided
with activation of Ca2þ-dependent ceramide kinase, and was
within the relevant time frame of arachidonic acid release [46].
These studies were the ¢rst to demonstrate a role for ceramide
kinase/Cer-1-P in signal transduction using a molecular ap-
proach, and have implicated Cer-1-P in the regulation of in-
£ammatory responses.
Fig. 3. Signaling cascades regulated by Cer-1-P. Stimulation of cer-
amide kinase results in Cer-1-P generation. Cer-1-P, by an unknown
mechanism, stimulates DNA synthesis, and increases proliferating
cell nuclear antigen levels and cell division. Alternatively, Cer-1-P
can increase cell numbers by blocking apoptosis through inhibition
of acid SMase (A-SMase). In addition, Cer-1-P activates cytosolic
(c) PLA2 initiating signaling through arachidonic acid (AA) release.
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The pathological and toxic e¡ects of Cer-1-P have been
recognized for some time since a SMase D was identi¢ed as
the active principle of the venom of the brown recluse spider
Loxosceles reclusa. SMase D can also be produced by some
bacteria including Corynebacterium pseudotuberculosis and Vi-
brio damsela [61]. The bite of this spider or infections caused
by these bacteria would induce in£ammatory responses that
are mediated by arachidonic acid release and subsequent gen-
eration of eicosanoids, and these actions might be controlled
by Cer-1-P.
Cer-1-P can be converted to other bioactive lipids, and
therefore one might hypothesize that the e¡ects of Cer-1-P
could be mediated through Cer-1-P-derived metabolites. How-
ever, ceramides and Cer-1-P are antagonistic signals, and Cer-
1-P is unable to mimic the e¡ects of sphingosine or Sph-1-P
(i.e. PLD activation or adenylyl cyclase inhibition) [42,43].
In addition, no ceramidases capable of converting Cer-1-P
to Sph-1-P have so far been identi¢ed in mammalian cells
(Fig. 3), and Sph-1-P does not inhibit acid SMase activity
in the manner that Cer-1-P does [39,44]. Therefore, Cer-1-P
is likely to act on its own to regulate cell activation. However,
conversion of ceramide to Cer-1-P might serve as a mecha-
nism to terminate the proapoptotic actions of ceramide,
and vice versa, dephosphorylation of Cer-1-P would cause
apoptosis. Whether or not these actions have physiological
relevance remains to be determined, but it was postulated
that at least part of the mechanism whereby ceramides block
the mitogenic e¡ect of Cer-1-P may involve stimulation of its
metabolism [42]. These observations emphasize the impor-
tance for cells to maintain a precise balance in the levels of
proapoptotic ceramides and antiapoptotic Cer-1-P, and sug-
gest that the ‘rheostat’ model proposed by Sarah Spiegel for
ceramides and Sph-1-P [62] can also be applied to ceramides
and Cer-1-P.
4. Speci¢city of Cer-1-P actions
A major concern when studying the functions of lipid me-
diators in metabolism is the speci¢city of action of the lipid
candidates. The detergent-like properties of lipids have been
known for a long time. Lipids can a¡ect the integrity of cell
membranes, causing loss of cytosolic components and cell
lysis. They can also induce non-speci¢c changes in the lipid
bilayer of cell membranes thereby leading to alterations in the
hydrophobic environment for optimal activity of membrane-
associated enzymes. Therefore, lipid speci¢city is a major re-
quirement when assessing the biological functions of bioactive
lipids in cells. Concerning Cer-1-P, Berger et al. [63] reported
that N-palmitoyl-Sph-1-P, which was complexed to bovine
serum albumin, stimulated the incorporation of thymidine
into DNA by about 7.9-fold in Swiss 3T3 ¢broblasts. By
contrast, N-palmitoyl-dihydro-Sph-1-P, which lacks the 4^5
trans double bond but retains the stereochemical con¢gura-
tion of Cer-1-P, had very little e¡ect on stimulating DNA
synthesis. Also, Cer-1-P shows signi¢cant speci¢city when
compared to other closely related phospholipids such as
Sph-1-P, PA, lyso-PA, phosphatidylcholine, phosphatidyleth-
anolamine, phosphatidylserine, or phosphatidylinositol. In
particular, among all of these phospholipids, only Cer-1-P
was able to signi¢cantly inhibit acid SMase in a cell-free sys-
tem [44]. This feature of Cer-1-P makes it suitable for use as a
selective inhibitor of acid SMase. In addition, the potency of
Cer-1-P to stimulate cell survival was superior for long-chain
Cer-1-P compared to short-chain Cer-1-Ps [44]. The e¡ect of
Cer-1-P in stimulating arachidonic acid release was also lipid-
speci¢c, as Sph-1-P, PA, diacylglycerol and ceramide were
ine¡ective [46]. In addition, treatment of A549 cells with
SMase D, which generates Cer-1-P at the plasma membrane
of cells, also increased arachidonic acid release [46]. The au-
thors of the latter work concluded that this e¡ect was speci¢c
for Cer-1-P, as pretreatment of the cells with SMase C, which
hydrolyzes membrane SM to generate ceramides and therefore
removes the substrate for SMase D, inhibited SMase D-in-
duced arachidonic acid release [46]. This work demonstrates
that SM is required for the action of SMase D and that Cer-1-
P is the primary product of SM hydrolysis responsible for
stimulating arachidonic acid release. Taken together these
studies demonstrate that the cellular activities of Cer-1-P are
speci¢c, and support a physiological role for Cer-1-P in con-
trolling cell activation.
5. Metabolism of Cer-1-P
Biosynthesis of Cer-1-P in mammalian cells is catalyzed by
ceramide kinase through phosphorylation of ceramides de-
rived from the breakdown of SM, gangliosides, or from de
novo synthesis (Fig. 2). The existence of ceramide kinase has
been known for over a decade [48], but it has not been cloned
until recently [64]. Subsequent identi¢cation of Cer-1-P phos-
phatase in rat brain [65] and hepatocytes [66] suggested that
ceramide and Cer-1-P are interconvertible in cells. Cer-1-P can
also be converted to ceramide by the action of a PA phos-
phohydrolase that is speci¢cally located in the plasma mem-
brane of cells [67]. It is now known that this enzyme activity
belongs to a family of at least three mammalian lipid phos-
phate phosphatases [68]. In addition, Cer-1-P could poten-
tially be formed by the action of SMase D, which occurs in
a variety of organisms [61]. However, no mammalian SMase
D activity has so far been detected.
6. Concluding remarks and future prospects
Cer-1-P has emerged as a new bioactive sphingolipid capa-
ble of regulating vital cellular functions. It stimulates cell pro-
liferation, blocks apoptosis, and is involved in phagocytosis
and in£ammation. By contrast, ceramides are potent inhibi-
tors of cell division and induce apoptosis in a great variety of
cell types. In particular, ceramides block cell proliferation
induced by mitogenic phospholipids (Cer-1-P, Sph-1-P, PA,
or lyso-PA). At least part of this negative regulation of cell
growth by ceramides may involve increased degradation of the
bioactive phospholipids, possibly by enhancing the activity of
speci¢c lipid phosphate phosphatases. Activation of SMases
to form ceramides may yield a proapoptotic signal. By con-
trast, conversion of ceramides to Cer-1-P would stimulate cell
division and block cell death. These actions suggest that reg-
ulation of the enzymes that are involved in the metabolism of
ceramides and Cer-1-P is vital for controlling the overall sig-
nal that is ¢nally transmitted in cells. At least one of the
mechanisms whereby Cer-1-P blocks apoptosis involves inhi-
bition of acid SMase. Because ceramide and Cer-1-P have
opposing e¡ects, these ¢ndings add a new dimension to the
understanding of the metabolic interrelationship of these me-
tabolites, and suggest that alterations in the balance of the
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intracellular levels of ceramides and Cer-1-P can a¡ect cell
survival. In addition, Cer-1-P enhances the activity of cyto-
solic PLA2 in several cell types including A549 lung adeno-
carcinoma cells, J774.1 macrophages, and L929 mouse ¢bro-
blasts, thereby promoting arachidonic acid release and the
subsequent biosynthesis of eicosanoids. The latter observation
indicates that Cer-1-P may be an important regulator of in-
£ammatory responses.
Up to now, it is not known whether Cer-1-P is present in
plasma, or if it can be released into the extracellular environ-
ment upon cell activation. A general feature in cell signaling
processes is that a signal, such as ceramide or Cer-1-P, is
generated by the action of an enzyme or a group of enzymes
acting in concert. The enzyme product will then activate spe-
ci¢c downstream e¡ectors leading to a cascade of metabolic
reactions that will end up stimulating or inhibiting a biolog-
ical function. A major challenge for future studies is to estab-
lish ¢rmly or to disprove the role of Cer-1-P as a second
messenger, and to de¢ne the signaling pathways that are regu-
lated by this novel bioactive sphingolipid. The simplest ap-
proach to achieve this is to continue to investigate whether
Cer-1-P can speci¢cally activate or inhibit known protein ki-
nases and phosphatases, both in vitro and in vivo. Other
approaches might include the use of photoa⁄nity techniques
with radioactive Cer-1-P, lipid^protein overlay assays, or large
multilamellar vesicle binding assays, so as to detect speci¢c
Cer-1-P binding proteins in cells. Also, a better understanding
of the interactions between the di¡erent metabolites that can
be generated from the SMase pathway would be critical for
elucidation of the mechanisms that regulate cellular functions,
in particular cell proliferation and death, as well as in£amma-
tion. Most importantly, the development of inhibitors or ac-
tivators of the enzymes that a¡ect the intracellular concentra-
tions of Cer-1-P may be crucial for establishing therapeutic
strategies for controlling metabolic disorders.
Much e¡ort is now required to elucidate the mechanisms of
action of Cer-1-P, and to de¢ne the physiological signi¢cance
of the intracellular formation of this bioactive sphingolipid.
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